237 related articles for article (PubMed ID: 8389853)
1. Characterization of indolidan- and rolipram-sensitive cyclic nucleotide phosphodiesterases in canine and human cardiac microsomal fractions.
Lugnier C; Muller B; Le Bec A; Beaudry C; Rousseau E
J Pharmacol Exp Ther; 1993 Jun; 265(3):1142-51. PubMed ID: 8389853
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the binding sites for the cardiotonic phosphodiesterase inhibitor [3H]LY186126 in ventricular myocardium.
Artman M; Robertson DW; Mahony L; Thompson WJ
Mol Pharmacol; 1989 Aug; 36(2):302-11. PubMed ID: 2505059
[TBL] [Abstract][Full Text] [Related]
3. Identification, characterization, and functional role of phosphodiesterase type IV in cerebral vessels: effects of selective phosphodiesterase inhibitors.
Willette RN; Shiloh AO; Sauermelch CF; Sulpizio A; Michell MP; Cieslinski LB; Torphy TJ; Ohlstein EH
J Cereb Blood Flow Metab; 1997 Feb; 17(2):210-9. PubMed ID: 9040501
[TBL] [Abstract][Full Text] [Related]
4. LY195115: a potent, selective inhibitor of cyclic nucleotide phosphodiesterase located in the sarcoplasmic reticulum.
Kauffman RF; Crowe VG; Utterback BG; Robertson DW
Mol Pharmacol; 1986 Dec; 30(6):609-16. PubMed ID: 2946929
[TBL] [Abstract][Full Text] [Related]
5. Characterization and pharmacological relevance of high affinity binding sites for [3H]LY186126, a cardiotonic phosphodiesterase inhibitor, in canine cardiac membranes.
Kauffman RF; Utterback BG; Robertson DW
Circ Res; 1989 Jul; 65(1):154-63. PubMed ID: 2544318
[TBL] [Abstract][Full Text] [Related]
6. Comparison of indolidan analog binding sites of drug antibody and sarcoplasmic reticulum with inhibition of cyclic AMP phosphodiesterase.
Ashikaga T; Robertson DW; Sportsman RJ; Strada SJ; Thompson WJ
J Recept Signal Transduct Res; 1996; 16(5-6):315-37. PubMed ID: 8968964
[TBL] [Abstract][Full Text] [Related]
7. Characterization and selective inhibition of cyclic nucleotide phosphodiesterase isozymes in canine tracheal smooth muscle.
Torphy TJ; Cieslinski LB
Mol Pharmacol; 1990 Feb; 37(2):206-14. PubMed ID: 2154670
[TBL] [Abstract][Full Text] [Related]
8. Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: correlation between function and interaction with a high-affinity rolipram binding site.
Barnette MS; Grous M; Cieslinski LB; Burman M; Christensen SB; Torphy TJ
J Pharmacol Exp Ther; 1995 Jun; 273(3):1396-402. PubMed ID: 7791113
[TBL] [Abstract][Full Text] [Related]
9. Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors.
Verghese MW; McConnell RT; Strickland AB; Gooding RC; Stimpson SA; Yarnall DP; Taylor JD; Furdon PJ
J Pharmacol Exp Ther; 1995 Mar; 272(3):1313-20. PubMed ID: 7891349
[TBL] [Abstract][Full Text] [Related]
10. Biochemical and pharmacological characterization of cyclic nucleotide phosphodiesterase in airway epithelium.
Rousseau E; Gagnon J; Lugnier C
Mol Cell Biochem; 1994 Nov; 140(2):171-5. PubMed ID: 7898488
[TBL] [Abstract][Full Text] [Related]
11. Initial biochemical and functional characterization of cyclic nucleotide phosphodiesterase isozymes in canine colonic smooth muscle.
Barnette MS; Manning CD; Price WJ; Barone FC
J Pharmacol Exp Ther; 1993 Feb; 264(2):801-12. PubMed ID: 7679736
[TBL] [Abstract][Full Text] [Related]
12. Characterization of phosphodiesterase 4 in guinea-pig macrophages: multiple activities, association states and sensitivity to selective inhibitors.
Kelly JJ; Barnes PJ; Giembycz MA
Br J Pharmacol; 1998 May; 124(1):129-40. PubMed ID: 9630352
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of human cardiac cyclic AMP-phosphodiesterases by R 80122, a new selective cyclic AMP-phosphodiesterase III inhibitor: a comparison with other cardiotonic compounds.
de Cheffoy de Courcelles D; de Loore K; Freyne E; Janssen PA
J Pharmacol Exp Ther; 1992 Oct; 263(1):6-14. PubMed ID: 1328613
[TBL] [Abstract][Full Text] [Related]
14. The ability of phosphodiesterase IV inhibitors to suppress superoxide production in guinea pig eosinophils is correlated with inhibition of phosphodiesterase IV catalytic activity.
Barnette MS; Manning CD; Cieslinski LB; Burman M; Christensen SB; Torphy TJ
J Pharmacol Exp Ther; 1995 May; 273(2):674-9. PubMed ID: 7752069
[TBL] [Abstract][Full Text] [Related]
15. Bemoradan--a novel inhibitor of the rolipram-insensitive cyclic AMP phosphodiesterase from canine heart tissue.
Moore JB; Combs DW; Tobia AJ
Biochem Pharmacol; 1991 Jul; 42(3):679-83. PubMed ID: 1650219
[TBL] [Abstract][Full Text] [Related]
16. Specific binding of [3H]LY186126, an analogue of indolidan (LY195115), to cardiac membranes enriched in sarcoplasmic reticulum vesicles.
Kauffman RF; Utterback BG; Robertson DW
Circ Res; 1989 May; 64(5):1037-40. PubMed ID: 2539921
[TBL] [Abstract][Full Text] [Related]
17. Cellular distribution and pharmacological sensitivity of low Km cyclic nucleotide phosphodiesterase isozymes in human cardiac muscle from normal and cardiomyopathic subjects.
Silver PJ; Allen P; Etzler JH; Hamel LT; Bentley RG; Pagani ED
Second Messengers Phosphoproteins; 1990; 13(1):13-25. PubMed ID: 2286932
[TBL] [Abstract][Full Text] [Related]
18. Biarylcarboxylic acids and -amides: inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emetic behavior in the ferret.
Duplantier AJ; Biggers MS; Chambers RJ; Cheng JB; Cooper K; Damon DB; Eggler JF; Kraus KG; Marfat A; Masamune H; Pillar JS; Shirley JT; Umland JP; Watson JW
J Med Chem; 1996 Jan; 39(1):120-5. PubMed ID: 8568798
[TBL] [Abstract][Full Text] [Related]
19. Suppression of human eosinophil respiratory burst and cyclic AMP hydrolysis by inhibitors of type IV phosphodiesterase: interaction with the beta adrenoceptor agonist albuterol.
Dent G; Giembycz MA; Evans PM; Rabe KF; Barnes PJ
J Pharmacol Exp Ther; 1994 Dec; 271(3):1167-74. PubMed ID: 7996422
[TBL] [Abstract][Full Text] [Related]
20. Identification, characterization and functional role of phosphodiesterase isozymes in human airway smooth muscle.
Torphy TJ; Undem BJ; Cieslinski LB; Luttmann MA; Reeves ML; Hay DW
J Pharmacol Exp Ther; 1993 Jun; 265(3):1213-23. PubMed ID: 8389856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
